

<b>INFORMATION DISCLOSURE CITATION</b>	<b>Docket No:</b> 3073.074	<b>Serial No.:</b> 10/597,290
	<b>Applicant(s):</b> NASH et al.	<b>Examiner:</b> EYLER, Yvonne L.
	<b>Filing Date:</b> 07/19/2006	<b>GAU:</b> 1614

**U.S. PATENT DOCUMENTS**

Examiner Initial	Ref	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						

**U.S. PATENT APPLICATION PUBLICATIONS**

Examiner Initial	Ref	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	BA	US 2003/152550	08/14/2003	Granucci et al.	A61K		07/31/2002
	BB						

**FOREIGN PATENT DOCUMENTS**

Examiner Initial	Ref	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
	CA	00/37465	06/29/2000	WO	CO7D	471/00		
	CB	2004/064715	08/05/2004	WO	A61K			

**OTHER DOCUMENTS**

*(Including Author, title, Date, Pertinent Pages, etc.)*

	DA	Tae S. KIM et al., "Induction of interleukin-12 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid, deviates CD4 <sup>+</sup> T cells from a Th2 to a Th1 response", Immunology 2003, Vol. 109(3), pp. 407-414.
	DB	Sheila A. NEWTON et al., "Swainsonine Inhibition of Spontaneous Metastasis", Journal of the National Cancer Institute, Vol. 81(13), 1989, pp. 1024-1028.
	DC	Alison A. WATSON et al., "Polyhydroxylated alkaloids – natural occurrence and therapeutic applications", Phytochemistry, Vol. 56, 2001, pp. 265-295.
	DD	M. YAGITA et al., "Swainsonine, an Inhibitor of Glycoprotein Processing, Enhances Cytotoxicity of Large Granular Lymphocytes", Scandinavian Journal of Immunology, Vol. 31(3), 1990, pp. 275-282.

EXAMINER:

Date Considered

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.**